Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance (original) (raw)
Islet cell antigen reactive CD8+ T cells and antibody collaborate to cause autoimmune diabetes in RIP-mOVA mice. To directly examine the consequences of antibody-enhanced cross-priming in the context of autoantibody and self antigen in vivo, we have looked at the development of autoimmune diabetes in RIP-mOVA mice (23). These mice express the model antigen OVA as “self” in the thymus and the β cells of the pancreas. Thymic expression of OVA leads to central tolerance; however, studies of peripheral tolerance are enabled by the transfer of OVA-specific naive T cells. Transfer of naive OT-I CD8+ transgenic T cells into RIP-mOVA adoptive recipients results in cross-tolerance due to OT-I deletional mechanisms (24). Loss of self tolerance is triggered either by the transfer of high numbers of OT-I cells or by the provision of T cell help (25), which leads to an OT-I CTL–mediated attack on the pancreatic islets of RIP-mOVA animals, resulting in diabetes. These studies utilized OT-I donor populations obtained from RAG1–/– backgrounds, while subsequent work in our laboratory has shown that CD8+ T cells obtained from OT-I TCR transgenic mice on conventional C57BL/6 backgrounds do not provoke diabetes even when transferred in large numbers (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI29470DS1).
In our initial experiments, mice were injected with naive CD8+ OT-I cells obtained from conventional OT-I TCR C57BL/6 mice, rabbit anti-OVA IgG, or both and then monitored over time for diabetes development. Staining of pancreatic cryosections showed that transferred rabbit anti-OVA IgG bound specifically to the islets of Langerhans in RIP-mOVA mice, approximating the expression pattern of OVA. However, despite binding, there was no evidence of a local pancreatic Arthus-like acute inflammatory response at 24 hours, nor was there any evidence of infiltration or glycosuria 7–20 days after the transfer of anti-OVA IgG alone (Figure 1 and Figure 2A; and data not shown). This data supports a lack of intrinsic pathogenicity of the antibody. In mice receiving OT-I cells alone, disease was extremely infrequent, with only 1 of 24 recipients developing diabetes, consistent with the induction of peripheral tolerance (Figure 1). Thus, neither anti-OVA IgG nor OT-I cells were capable by themselves of inducing diabetes. In contrast, when anti-OVA IgG was administered together with the OT-I cells, diabetes was synergistically induced in a manner dependent on the dose of the antibody, with all mice developing disease at 1,000 μg of anti-OVA IgG (Figure 1). Diabetic animals sustained severe glycosuria (urine glucose ≥1,000 mg/dl) and hyperglycemia (blood glucose >400 mg/dl), with a disease onset of 6–9 days after treatment. These findings clearly demonstrate the ability of antibody to drive T cell–mediated autoimmunity in this system.
OT-I cells and anti-OVA IgG synergistically induce diabetes. Diabetes incidence: RIP-mOVA mice were injected with 5 × 106 OT-I cells alone or together with administration of rabbit anti-OVA IgG, control rIgG, an F(ab′)2 fragment of rabbit anti-OVA IgG, or murine polyclonal anti-OVA IgG. Anti-OVA refers to rabbit anti-OVA IgG unless otherwise noted. Fractions below bars indicate the number of diabetic mice over the total number treated. Diabetes was not induced by transfer of OVA-specific antibodies and rarely by OT-I cells alone but was synergistically induced by transfer of both OT-I cells and anti-OVA IgG.
Anti-OVA IgG drives OT-I cell infiltration into the pancreas. (A) Anti-OVA IgG binds to the islets of Langerhans without causing acute inflammation. Staining for OVA (left), bound anti-OVA IgG (by detecting rIgG; middle), and H&E (right) in the pancreata of RIP-mOVA mice 24 hours after treatment with 1,000 μg anti-OVA IgG or 1,000 μg control rIgG (insets). Transferred anti-OVA IgG bound to islet cells (middle) but did not trigger infiltrative lesions (right). (B and C) Diabetes results from OT-I cell infiltration into the pancreas. H&E, CD8 (red), and OVA (green) staining on pancreatic sections (B) and flow cytometric analysis of total live pancreatic cells (C) from RIP-mOVA mice 7 days after transfer of either OT-I cells alone or together with 1,000 μg anti-OVA IgG. Vα2 and Vβ5 indicate the presence of OT-I TCR+ cells. Destructive cellular infiltrates were observed after the transfer of T cells and anti-OVA IgG, including massive intraislet CD8+ OT-I cell accumulation, whereas T cells transferred alone did not accumulate in the pancreas nor induced inflammatory responses.
No diabetes occurred with the transfer of OT-I cells and control nonimmune polyclonal rabbit IgG (rIgG), underscoring the requirement for islet-specific antibody in disease development (Figure 1). In addition, administration of 1,000 μg of a F(abι)2 fragment of the polyclonal rabbit anti-OVA IgG, along with OT-I cells, also did not cause diabetes, implicating the Fc portion of the antibody in disease development (Figure 1). To address the possibility that these results might simply demonstrate an effect of the xenogenic rIgG, polyclonal murine anti-OVA IgG was transferred into RIP-mOVA mice. Two of 4 mice receiving OT-I cells plus 8 mg of the murine polyclonal antibody developed diabetes by day 7 (Figure 1), while transfer of murine anti-OVA IgG alone did not induce diabetes (n = 2). This shows that both rabbit and murine polyclonal anti-OVA IgG are able to induce diabetes synergistically with OT-I cells. The apparent greater potency of the rabbit anti-OVA IgG can be explained in part by the relative titers of the 2 polyclonal preparations. The rabbit anti-OVA IgG had a 44-fold higher OVA-binding activity than the murine anti-OVA IgG, making the 2 preparations relatively equal in terms of disease-inducing ability (Supplemental Figure 2).
Histologically, diabetes induced by combined OT-I cell and anti-OVA IgG transfer was marked by widespread inflammatory lesions in the pancreata of all mice examined. Starting progressively on day 3, lymphocytes were seen in perivascular regions and throughout the pancreatic exocrine tissue, as well as surrounding and infiltrating the islets of Langerhans. Numerous pyknotic nuclei were present, indicating cellular apoptosis of both the islet and adjacent acinar cells. By days 5–7, near obliterative lesions were seen in the remnant islets, coinciding with the appearance of severe glycosuria (Figure 2B and Table 1). As expected, immunofluorescence staining demonstrated numerous CD8+ cells within infiltrative islet lesions, and flow cytometric analysis showed a significant population of OT-I cells (Vα2+Vβ5+) within the pancreas of diabetic animals, consistent with OT-I CTL–mediated destruction (Figure 2, B and C). In the peri-islet areas, various other infiltrating cell types were also detected, including CD4+, Gr1+, and CD11b+ cells (data not shown). In the absence of antibody, very few lymphocytes entered the pancreas and neither inflammatory lesions nor intraislet CD8+ T cells were present (Figure 2, B and C). Thus, the cotransfer of autoreactive antibody was required to trigger massive OT-I cell–mediated inflammation and destructive insulitis in the pancreas of RIP-mOVA mice.
Histopathological scores of mice treated with OT-I cells with or without anti-OVA
In vivo OT-I cell priming is enhanced by anti-OVA IgG. Antibody is known to augment uptake and processing of cognate antigen by DCs, leading to efficient T cell priming. Therefore, to address the mechanism by which anti-OVA IgG induces OT-I cells to cause diabetes, we began by looking at initial priming events in the draining pancreatic lymph node. RIP-mOVA mice received 5 × 106 CFSE-labeled OT-I cells with or without anti-OVA IgG, and proliferative responses were assessed 3 days later. As has been previously described (26), transferred OT-I cells underwent proliferation in the pancreatic lymph node, presumably due to ongoing cross-presentation of OVA by lymph node DCs. However, upon addition of anti-OVA IgG, OT-I cell proliferation was consistently amplified 1.5- to 2-fold (Figure 3A), indicating the ability of anti-OVA IgG to boost the presentation of OVA in the draining lymph node to incoming T cells. Furthermore, enhanced OT-I cell proliferation in the presence of anti-OVA IgG led to an even greater augmentation in effector OT-I cell differentiation, as assessed by IFN-γ production 5 days after transfer. ELISPOT analysis showed a dramatic increase in the number of cells producing IFN-γ in the pancreatic lymph node of antibody-treated mice compared with those receiving only T cells (Figure 3B). This effect was specific to the draining pancreatic lymph node, as IFN-γ production was not similarly enhanced in the nondraining brachial lymph node and only slightly so in the spleen. In order to identify the specific cell population responsible for the IFN-γ production, intracellular detection of this cytokine was performed. Gating on the transferred OT-I cell population showed that these cells were the primary producers of IFN-γ in the pancreatic lymph node and that in the presence of rabbit anti-OVA IgG, 5-fold more of these cells differentiated into IFN-γ–producing effectors (Figure 3C). Collectively, these data show that antibody not only enhances OT-I cell proliferation in the draining lymph node, but it also alters the qualitative outcome of self-antigen recognition, driving proliferating T cells to differentiate into effector CTLs.
Anti-OVA IgG enhances functional antigen presentation in the pancreatic lymph node. (A) OT-I cell proliferative responses. Pancreatic lymph node cells isolated from RIP-mOVA mice 3 days after transfer of CFSE-labeled OT-I cells and anti-OVA IgG. Dot plots are gated on CD8+CFSE+ cells. Proliferation was enhanced 2-fold in recipients of OT-I cells and anti-OVA IgG. (B and C) OT-I cell effector differentiation. ELISPOT analysis of IFN-γ production by total lymph node and splenic cells (B) and intracellular IFN-γ staining of pancreatic lymph node OT-I cells (C) isolated from RIP-mOVA mice 5 days after treatment. Bars show mean ± SD for triplicate wells of 1 representative experiment out of 3. Dot plots are gated on CD8+Vα2+Vβ5+ cells. Differentiation of OT-I cells into IFN-γ–producing effectors was significantly (P = 1.06 × 10–6) enhanced in the presence of anti-OVA IgG.
Anti-OVA IgG enhances the presentation of apoptotic cell antigen. We sought to determine the nature of the antibody-opsonized antigen responsible for enhanced presentation in the pancreatic lymph node. Anti-OVA IgG could bind to OVA on the membrane or OVA released from viable β islet cells, as well as opsonized apoptotic β islet corpses that are constantly being produced by steady-state β cell death (27). To ascertain the role of apoptosis, RIP-mOVA mice were treated with the pan-caspase inhibitor ZVAD, which has been used pharmacologically in a study implicating apoptotic cells as a source of antigenic material (27). Mice were treated with ZVAD 24 hours prior to the injection of anti-OVA IgG and OT-I cells. Antibody-enhanced OT-I cell proliferation was abrogated in ZVAD-treated mice, indicating that apoptotic islet cells are the likely source of opsonized antigenic material (Figure 4). This effect was not due to enhanced β islet cell apoptosis resulting from antibody binding, as islets from anti-OVA IgG– and rIgG-treated mice contained similar numbers of TUNEL-positive cells at 24 and 72 hours after antibody transfer (data not shown). Notably, steady-state OT-I cell proliferation in the pancreatic lymph node was not eliminated in ZVAD-treated mice, likely because apoptotic material persists in the node for more than 24 hours. Despite clear inhibition of the initial OT-I cell proliferative burst, reflective of decreased levels of antigen presentation, continued ZVAD treatment did not prevent the development of diabetes in RIP-mOVA mice (n = 5; data not shown). The persistence of disease may result from the antiapoptotic effects of ZVAD on additional cellular targets, including the responding OT-I cells themselves, which would otherwise be deleted (24, 28). This idea is supported by the fact that inhibition of T cell expansion was no longer apparent by day 5, when normal or increased numbers of OT-I cells were found in the pancreatic lymph nodes of ZVAD-treated animals (Supplemental Figure 3). Thus, despite the confounding effects of ZVAD on OT-I cell accumulation/survival, the early block of antibody-enhanced OT-I cell proliferation is directly indicative of the contribution of β islet cell apoptosis to antigen presentation.
Anti-OVA IgG enhances OT-I cell proliferation in response to apoptotic cell antigen. Flow cytometric analysis of pancreatic lymph node cells isolated from ZVAD-treated and untreated RIP-mOVA mice 3 days after transfer of CFSE-labeled OT-I cells with or without anti-OVA IgG. Histograms show percentage of cells divided relative to total CD8+CFSE+ cells. Data represent 1 of 2 independent experiments. Antibody-enhanced OT-I cell proliferation was abolished in ZVAD-treated mice (right).
DCs are required for the in vivo cross-presentation of OVA. DCs have been implicated as the relevant cross-presenting cell for tolerogenic and diabetogenic presentation of islet antigen in the draining pancreatic lymph node (29). In ex vivo analysis, both CD11b–CD8+ and CD11b+CD8– DCs have been shown to be responsible (27, 30). Therefore, we were interested in the importance of DCs for both the steady-state and antibody-enhanced proliferation seen in vivo in RIP-mOVA mice. To this end, we took advantage of CD11c–diphtheria toxin receptor (CD11c-DTR) mice, which express a human high-affinity DTR on the surface of CD11c+ cells, making them specifically sensitive to diphtheria toxin–mediated (DT-mediated) apoptosis (31). Using this DC depletion model, DCs have been previously shown to be required for the cross-presentation of cell-associated (31) and soluble exogenous antigen (32), as well as for the presentation of bacterial (31) and viral antigens (33, 34). Preliminary experiments in DT-treated WT and CD11c-DTR mice showed that transferred OT-I cells accumulated and localized to the T cell zones of the lymph nodes and spleen in comparable numbers regardless of the presence or absence of CD11c+ cells (Supplemental Figure 4). Therefore, DT-treated RIP-mOVA and RIP-mOVA/CD11c-DTR mice were transferred with 5 × 106 CFSE-labeled OT-I cells with or without anti-OVA IgG, and proliferation was assessed after 3 days. Strikingly, no proliferation of the OT-I cells was seen in the pancreatic lymph node of DC-depleted recipient mice, regardless of whether the mice also received anti-OVA IgG (Figure 5). In order to confirm our findings and rule out roles for subpopulations of marginal zone splenic macrophages (35), we transferred CD11c+ splenic cells isolated from WT mice into DT-treated RIP-mOVA/CD11c-DTR recipients and once again assessed OT-I cell proliferative responses. Reconstitution of RIP-mOVA/CD11c-DTR mice with 5 × 106 CD11c+ cells, injected i.v. prior to DT treatment, led to only 30% DC reconstitution in the pancreatic lymph node. However, this transfer was sufficient to restore steady-state and antibody-triggered OT-I cell proliferation (Supplemental Figure 5). Therefore, these data cumulatively demonstrate that CD11c+ DCs are the required APCs for both steady-state and antibody-enhanced cross-presentation of self antigen in the pancreatic lymph node of RIP-mOVA mice.
DCs are required for steady-state and antibody-enhanced OT-I cell proliferation in the pancreatic lymph node. Flow cytometric analysis of pancreatic lymph node cells isolated from DT-treated RIP-mOVA and RIP-mOVA/CD11c-DTR mice 3 days after transfer of CFSE-labeled OT-I cells alone (left panels) or together with anti-OVA IgG (right panels). Dot plots are gated on CD8+CFSE+ cells and represent 1 of 3 independent experiments. OT-I cell proliferative responses were abolished in the absence of DCs (bottom panels).
We next examined whether immunization with OVA IC-loaded DCs was sufficient to break peripheral tolerance in RIP-mOVA mice. Animals were immunized intravenously with either OVA-loaded or OVA IC–loaded BM-derived DCs (BMDCs), prior to the transfer of 5 × 106 OT-I cells. All 3 mice receiving OVA IC–loaded BMDCs developed diabetes, while none of 3 mice immunized with OVA-loaded BMDCs became diabetic (data not shown). Thus, the targeting of ICs to DCs is both necessary and sufficient for overcoming cross-tolerance in vivo.
Lethal induction of antibody-triggered diabetes requires activating FcγRs and complement. In order to determine the contribution of the activating FcγR and complement pathways to the antibody-triggered induction of CTL-mediated autoimmunity, RIP-mOVA FcγRγ–/–, RIP-mOVA C3–/–, and RIP-mOVA FcγRγ–/–C3–/– mice were generated. The absence of the γ chain associated with FcγRI, -III, and -IV prevents expression of these activating FcγRs (36, 37) on the cell surface, while C3–/– mice can no longer carry out the classical or alternative complement cascades (38). Examination of these mice for disease development in response to the transfer of OT-I cells and anti-OVA IgG revealed that elimination of either activating FcγRs or C3 resulted in a significant, though not complete, reduction in disease incidence. Diabetes developed in approximately 40% of RIP-mOVA mice deficient in either FcγRγ or C3, compared with 100% of WT RIP-mOVA mice (Figure 6A). In addition, the severity of the diabetic illness in mice lacking activating FcγRs or C3 was greatly attenuated. These animals often exhibited only transient glycosuria (with a range of 12–152 days), and all mice survived their course of illness, whereas diabetes was unrelenting in all WT RIP-mOVA mice, resulting in 75% lethality by 47 days (Figure 6B). Histopathological scores of insulitis and exocrine tissue inflammation among groups were consistent with their respective disease incidences (Table 1). Notably, however, insulitis in recipients of OT-I cells alone was more prominent in RIP-mOVA C3–/– mice than in the other genotypes. RIP-mOVA FcγRγ–/–C3–/– mice were completely protected from diabetes, with no mice developing glycosuria or hyperglycemia. These data indicate that complement and activating FcγRs are required together for maximal penetrance and severity of diabetes in recipients of anti-OVA IgG and OT-I cells.
Mice lacking activating Fcγ receptors and complement are protected from severe antibody-induced diabetes. (A) Diabetes incidence. RIP-mOVA, RIP-mOVA FcγRγ–/–, RIP-mOVA C3–/–, and RIP-mOVA FcγRγ–/–C3–/– mice were injected with 5 × 106 OT-I cells alone or together with 1,000 μg anti-OVA IgG. Fractions below bars indicate the number of diabetic mice over the total number treated. Diabetes occurred in 100% of antibody-treated WT RIP-mOVA mice compared with 41% of FcγRγ–/–, 35% of C3–/–, and 0% of FcγRγ–/–C3–/– mice (P = 2 × 10–6, 5 × 10–7, and 8 × 10–10, respectively). (B) Survival of WT, FcγRγ–/–, and C3–/– mice. Kaplan-Meier curves of RIP-mOVA mice (black) compared with RIP-mOVA FcγRγ–/– mice (gray, left) and RIP-mOVA C3–/– mice (gray, right) after transfer of OT-I cells and anti-OVA IgG (***P = 1 × 10–4). Diabetes was severe and usually lethal in WT mice. In contrast, disease severity was attenuated in FcγRγ–/– and C3–/– mice, with no mice developing fatal diabetes.
Antibody-mediated cross-priming of self antigen is dependent on activating FcγRs and not on complement C3. To address the mechanistic contributions of activating FcγRs and complement to the loss of tolerance in RIP-mOVA mice, we have assessed their requirement in antibody-mediated cross-priming in the draining pancreatic lymph node. Strikingly, RIP-mOVA mice lacking activating FcγRs no longer showed antibody-enhanced OT-I cell proliferation, while steady-state cross-presentation of OVA in the pancreatic lymph node was unchanged (Figure 7A). Further, intracellular cytokine staining revealed no significant antibody-driven enhancement of IFN-γ production when activating FcγRs were absent (Figure 7C). Thus, while activating FcγRs on additional cell types may also ultimately contribute to pancreatic injury, these findings, in conjunction with the DC requirement for OT-I cell proliferation (Figure 5), indicate the importance of activating FcγRs on DCs in the cross-priming of T cells to antibody-bound islet antigen.
Antibody-enhanced OT-I cell proliferation and effector cell differentiation is dependent on activating Fcγ receptors. (A and B) OT-I cell proliferative responses in WT, FcγRγ–/–, and C3–/– mice. Flow cytometric analysis of pancreatic lymph node cells isolated from RIP-mOVA, RIP-mOVA FcγRγ–/–, and RIP-mOVA C3–/– mice (A) and ZVAD-treated and untreated RIP-mOVA C3–/– mice (B) 3 days after transfer of CFSE-labeled OT-I cells and anti-OVA IgG. The percentage of cells divided (A) and the numbers in the histogram (B) were calculated from FACS plots gated on CD8+CFSE+ cells found after the undivided peak. Bars show mean ± SD for at least 5 mice per treatment group. *P = 0.033; †0.0085; **P = 0.00040; #P = 0.00060; NS: P = 0.46. Histogram represents 1 of 2 independent experiments. Activating FcγRs were required for antibody-enhanced proliferation, whereas C3 negatively regulated T cell proliferation in a ZVAD-inhibitable manner. (C) OT-I cell effector differentiation in WT, FcγRγ–/–, and C3–/– mice. Intracellular IFN-γ staining of pancreatic lymph node cells isolated from mice 5 days after treatment. The percentage of cells producing IFN-γ was calculated from IFN-γ–positive cells among CD8+Vα2+Vβ5+-gated populations. Bars show mean ± SD for at least 3 mice per group. ***P = 1.06 × 10–6; ††P = 0.00048; ##P = 0.016; ζ_P_ = 0.037; NS: P = 0.28. Antibody enhancement of IFN-γ production was intact in C3–/– but not FcγRγ–/– mice.
On the other hand, C3 was not required for antibody-enhanced cross-priming of the OT-I cells. Interestingly, however, the steady-state level of T cell proliferation was significantly enhanced in RIP-mOVA C3–/– mice (Figure 7A). These data suggest a negative regulatory role for complement in steady-state antigen presentation in the pancreatic lymph node. In particular, C3 appeared to be regulating the cross-presentation of apoptotic material, as enhanced steady-state OT-I cell proliferation did not occur in ZVAD-treated animals (Figure 7B). Similar results were obtained when effector OT-I cell differentiation was assessed (Figure 7C). In the absence of antibody, a 3-fold greater frequency of IFN-γ–producing OT-I cells was generated in RIP-mOVA C3–/– mice compared with WT RIP-mOVA mice. However, in the presence of antibody, the frequency of OT-I effector cells increased further still, underscoring the lack of requirement for C3 in antibody-enhanced T cell priming.
Antibody-mediated cross-priming and diabetes is inhibited by FcγRIIB. The ability of murine anti-OVA antibodies to trigger OT-I cell–mediated diabetes was further addressed in RIP-mOVA mice lacking the inhibitory FcγRIIB. We have shown elsewhere that RIP-mOVA FcγRIIB–/– animals are more sensitive to antibody-induced diabetes than WT RIP-mOVA mice (7). In these studies, a 10-fold-reduced dose of the rabbit polyclonal anti-OVA IgG (100 μg) was subdiabetogenic in WT RIP-mOVA recipients of OT-I cells but was fully diabetogenic in mice lacking FcγRIIB. Similarly, the murine polyclonal anti-OVA IgG exhibited enhanced pathogenicity in RIP-mOVA FcγRIIB–/– animals, with 50% of the mice developing diabetes after the transfer of OT-I cells and administration of a reduced dose (1 mg) of the murine antibody (Figure 8A). At this reduced dose of murine anti-OVA IgG, WT RIP-mOVA mice did not develop diabetes, consistent with a tolerogenic role for FcγRIIB. In addition to the murine polyclonal anti-OVA IgG, 2 murine monoclonal anti-OVA antibodies of the IgG1 and IgG2b subclasses were developed that demonstrated OVA-binding activities similar to the murine polyclonal antibody (Supplemental Figure 2B). These mAbs induced diabetes in WT RIP-mOVA recipients (2 of 11) and showed enhanced pathogenicity in RIP-mOVA FcγRIIB–/– mice (4 of 8) (Figure 8A). However, disease induction required higher doses of these 2 mAbs, which could be due to their epitope specificity, low avidity, or heavy chain subclass or instead might indicate that pathogenicity is favored by the increased valence provided by polyclonal antibodies.
FcγRIIB negatively regulates antibody-mediated OT-I cell priming. (A) Diabetes incidence. RIP-mOVA or RIP-mOVA FcγRIIB–/– mice were injected with 5 × 106 OT-I cells plus either 1 mg murine polyclonal anti-OVA IgG or murine monoclonal anti-OVA IgG. For the murine monoclonal anti-OVA IgG, 6 WT and 5 FcγRIIB–/– mice were transferred with 18 mg anti-OVA IgG2b, and 5 WT and 3 FcγRIIB–/– mice were transferred with 42 mg anti-OVA IgG1. Fractions below bars indicate the number of diabetic mice over the total number treated. Both the murine polyclonal antibodies and mAbs showed increased diabetogenicity in mice lacking FcγRIIB. (B) OT-I cell effector differentiation. Intracellular IFN-γ staining on pancreatic lymph node OT-I cells isolated from mice 5 days after transfer of OT-I cells alone or together with 1 mg murine polyclonal anti-OVA IgG. Dot plots are gated on CD8+Vα2+Vβ5+ cells.
To directly investigate the cross-priming ability of murine anti-OVA IgG, OT-I cell effector differentiation in the pancreatic lymph nodes of RIP-mOVA FcγRIIB–/– and WT RIP-mOVA mice was compared. Consistent with diabetes incidence, OT-I cell effector differentiation was induced in RIP-mOVA FcγRIIB–/– but not in WT RIP-mOVA recipients of OT-I cells and 1 mg murine polyclonal anti-OVA IgG (Figure 8B). These data are consistent with a role for FcγRIIB in limiting antibody-mediated cross-priming.